ENDLOS-TURBO CALL - ELI LILLY & CO Stock

ENDLOS-TURBO CALL - ELI LILLY & CO Share Price

Certificat

DE000DJ1D918

Delayed Deutsche Boerse AG 02:04:45 10/11/2023 am IST
18.05 ^EUR	-15.14%

1 month	+6.62%
3 months	+42.58%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ELI LILLY AND COMPANY

Chart ENDLOS-TURBO CALL - ELI LILLY & CO

Latest news about ELI LILLY AND COMPANY

Augustine Therapeutics N.V. announced that it expects to receive funding from a group of investors	26/06	CI
Top Midday Stories: Microsoft Hit with EU Antitrust Charges; Judge Blocks Swipe-Fee Settlement Between Visa, Mastercard and Retailers; Novo Nordisk Secures Chinese Approval for Weight-Loss Drug; Tesla, Ford Issue Recalls	25/06	MT
Eli Lilly Working With OpenAI to Develop Medicines Against Drug-Resistant Pathogens	25/06	DJ
Eli Lilly Teams Up With OpenAI to Develop Antimicrobials for Drug-Resistant Bacteria	25/06	MT

More news

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	ELI LILLY AND COMPANY
Issuer	DZ BANK
WKN	DJ1D91
ISIN	DE000DJ1D918
Date issued	02/05/2023
Strike	396.5 $
Maturity	Unlimited
Parity	10 : 1
Emission price	1.16 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	21.86 €
Lowest since issue	1.77 €

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Sector

More about the company